FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3045145863> ?p ?o ?g. }

• W3045145863 endingPage "191.e16" @default.
• W3045145863 startingPage "191.e9" @default.
• W3045145863 abstract "To investigate the impact of chronic kidney disease (CKD) on oncological outcomes in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who underwent adjuvant induction bacillus Calmette-Guérin (BCG) therapy after transurethral resection of bladder tumor (TURBT). We conducted a multi-institutional retrospective study assessing 209 patients with high-risk NMIBC who underwent TURBT and subsequent adjuvant induction BCG therapy from December 1998 to April 2019. Patients were divided into 2 groups: those with preoperative estimated glomerular filtration rate (eGFR) ≥ 60 ml/min/1.73 m2 (non-CKD group), and those with eGFR < 60 ml/min/1.73 m2 (CKD group). Primary endpoints were intravesical recurrence-free survival (RFS) and muscle-invasive bladder cancer (MIBC)-free survival. Background-adjusted multivariate analyses with the inverse probability of treatment weighting (IPTW) method using the propensity score were performed to evaluate the impact of CKD on intravesical RFS, MIBC-free survival, metastasis-free survival, cancer-specific survival, and overall survival. Moreover, multivariable analyses were performed to assess the impact of CKD on intravesical recurrence and MIBC progression, adjusting for the competing risk of death using the Fine-Gray competing risk regression model. Median age and follow-up period after TURBT were 72 years and 45 months, respectively. Of 209 patients, 71 (34%) were diagnosed with CKD before TURBT. Background-adjusted multivariate analyses with the IPTW method indicated that CKD was significantly associated with shorter intravesical RFS, MIBC-free survival, metastasis-free survival, cancer-specific survival, and overall survival. In the Fine-Gray competing risk regression model, CKD showed significantly higher probabilities of intravesical recurrence and MIBC progression, with an adjusted subdistribution hazard ratio of 1.886 (95% confidence interval 1.069–3.330, P = 0.028) and 3.740 (95% confidence interval 1.060–13.20, P = 0.040), respectively. CKD presents a risk factor of poor oncological outcomes in patients with high-risk NMIBC who underwent adjuvant induction BCG therapy after TURBT." @default.
• W3045145863 created "2020-07-29" @default.
• W3045145863 creator A5000893018 @default.
• W3045145863 creator A5009377685 @default.
• W3045145863 creator A5013782799 @default.
• W3045145863 creator A5016000795 @default.
• W3045145863 creator A5026803124 @default.
• W3045145863 creator A5033127294 @default.
• W3045145863 creator A5034118045 @default.
• W3045145863 creator A5044499778 @default.
• W3045145863 creator A5066536967 @default.
• W3045145863 creator A5066871291 @default.
• W3045145863 creator A5076273759 @default.
• W3045145863 creator A5080302805 @default.
• W3045145863 creator A5081170605 @default.
• W3045145863 creator A5089983384 @default.
• W3045145863 date "2021-03-01" @default.
• W3045145863 modified "2023-09-30" @default.
• W3045145863 title "Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy" @default.
• W3045145863 cites W2007682549 @default.
• W3045145863 cites W2016840392 @default.
• W3045145863 cites W2029785070 @default.
• W3045145863 cites W2038981426 @default.
• W3045145863 cites W2041656718 @default.
• W3045145863 cites W2058887964 @default.
• W3045145863 cites W2094156327 @default.
• W3045145863 cites W2104843066 @default.
• W3045145863 cites W2110818436 @default.
• W3045145863 cites W2116250664 @default.
• W3045145863 cites W2134791218 @default.
• W3045145863 cites W2148873696 @default.
• W3045145863 cites W2150951369 @default.
• W3045145863 cites W2152189242 @default.
• W3045145863 cites W2156617860 @default.
• W3045145863 cites W2281005747 @default.
• W3045145863 cites W2403627759 @default.
• W3045145863 cites W2405832424 @default.
• W3045145863 cites W2472727723 @default.
• W3045145863 cites W2531894893 @default.
• W3045145863 cites W2535533723 @default.
• W3045145863 cites W2592133588 @default.
• W3045145863 cites W2608267696 @default.
• W3045145863 cites W2969983122 @default.
• W3045145863 cites W2972369537 @default.
• W3045145863 cites W2973223476 @default.
• W3045145863 cites W2980171775 @default.
• W3045145863 cites W3011462671 @default.
• W3045145863 cites W3013893613 @default.
• W3045145863 cites W3016004425 @default.
• W3045145863 doi "https://doi.org/10.1016/j.urolonc.2020.06.032" @default.
• W3045145863 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32713622" @default.
• W3045145863 hasPublicationYear "2021" @default.
• W3045145863 type Work @default.
• W3045145863 sameAs 3045145863 @default.
• W3045145863 citedByCount "2" @default.
• W3045145863 countsByYear W30451458632022 @default.
• W3045145863 crossrefType "journal-article" @default.
• W3045145863 hasAuthorship W3045145863A5000893018 @default.
• W3045145863 hasAuthorship W3045145863A5009377685 @default.
• W3045145863 hasAuthorship W3045145863A5013782799 @default.
• W3045145863 hasAuthorship W3045145863A5016000795 @default.
• W3045145863 hasAuthorship W3045145863A5026803124 @default.
• W3045145863 hasAuthorship W3045145863A5033127294 @default.
• W3045145863 hasAuthorship W3045145863A5034118045 @default.
• W3045145863 hasAuthorship W3045145863A5044499778 @default.
• W3045145863 hasAuthorship W3045145863A5066536967 @default.
• W3045145863 hasAuthorship W3045145863A5066871291 @default.
• W3045145863 hasAuthorship W3045145863A5076273759 @default.
• W3045145863 hasAuthorship W3045145863A5080302805 @default.
• W3045145863 hasAuthorship W3045145863A5081170605 @default.
• W3045145863 hasAuthorship W3045145863A5089983384 @default.
• W3045145863 hasConcept C121608353 @default.
• W3045145863 hasConcept C126322002 @default.
• W3045145863 hasConcept C126894567 @default.
• W3045145863 hasConcept C143998085 @default.
• W3045145863 hasConcept C159641895 @default.
• W3045145863 hasConcept C167135981 @default.
• W3045145863 hasConcept C2775910329 @default.
• W3045145863 hasConcept C2777982462 @default.
• W3045145863 hasConcept C2778653478 @default.
• W3045145863 hasConcept C2780352672 @default.
• W3045145863 hasConcept C38180746 @default.
• W3045145863 hasConcept C71924100 @default.
• W3045145863 hasConceptScore W3045145863C121608353 @default.
• W3045145863 hasConceptScore W3045145863C126322002 @default.
• W3045145863 hasConceptScore W3045145863C126894567 @default.
• W3045145863 hasConceptScore W3045145863C143998085 @default.
• W3045145863 hasConceptScore W3045145863C159641895 @default.
• W3045145863 hasConceptScore W3045145863C167135981 @default.
• W3045145863 hasConceptScore W3045145863C2775910329 @default.
• W3045145863 hasConceptScore W3045145863C2777982462 @default.
• W3045145863 hasConceptScore W3045145863C2778653478 @default.
• W3045145863 hasConceptScore W3045145863C2780352672 @default.
• W3045145863 hasConceptScore W3045145863C38180746 @default.
• W3045145863 hasConceptScore W3045145863C71924100 @default.
• W3045145863 hasFunder F4320334764 @default.
• W3045145863 hasIssue "3" @default.
• W3045145863 hasLocation W30451458631 @default.

• next